课题基金 / 基金详情

Endothelial dysfunction in aged Trx-deficient mice.

Endothelial dysfunction in aged Trx-deficient mice.
老年 Trx 缺陷小鼠的内皮功能障碍。
批准号:
8851123
负责人:
KUMUDA C DAS
金额:
$6.78万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-06-21 至 2017-05-31

项目摘要

项目成果

KUMUDA C DAS的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):内皮功能障碍是心脏缺血-再灌注损伤的潜在分子机制,并已显示影响心肌梗死的梗死面积。心肌梗塞和其他冠心病是主要的健康问题,仅在美国就特别影响数百万老年人。这种损伤的发生部分是由于氧化应激引起的内皮功能障碍,当血管再灌注缺血的心脏组织时,氧化应激会增加。因此,调节心脏的氧化还原环境的药剂可潜在地用于治疗冠心病。出于这个原因,我们的实验室一直在表征硫氧还蛋白(Trx),这是一种内源性酶,可以减少氧化应激并再生因氧化而失活的蛋白质。结合这项研究,我们开发了两个转基因小鼠品系,改变了Trx的活性:一个(Trx-Tg)过表达的蛋白质,而其他(dnTrx-Tg)表达一个无活性的Trx,从而作为一个条件Trx敲除。当我们表征这些独特的小鼠时,我们发现老年TrxTg小鼠响应于缺血-再灌注(I/R)而免受心肌梗死,而那些缺乏Trx的小鼠,如野生型,经历广泛的心肌损伤。因此,我们假设,增加Trx活性水平可以提供保护,防止内皮功能障碍。这一假设导致了本提案的具体目标:目标1将确定Trx在I/R损伤引起的内皮功能障碍中的作用;目标2将探索这些作用的潜在机制;目标3将确定Trx是否增加线粒体超氧化物歧化酶的表达,作为保护内皮功能障碍的一个贡献者。该项目的结果将有助于我们理解心血管疾病如动脉粥样硬化中的内皮细胞功能障碍,并推动Trx作为治疗心血管疾病的真实的新治疗方法的发展,因为外源性添加的Trx被内皮细胞贪婪地摄取。
英文摘要
DESCRIPTION (provided by applicant): Endothelial dysfunction is an underlying molecular mechanism in ischemia-reperfusion injury of the heart, and has been shown to affect infarct size in myocardial infarction. Myocardial infarction and other coronary heart disease are major health problem that especially affects millions of older people in the United States alone. This damage occurs in part in response to endothelial dysfunction caused by oxidative stress, which increases when blood vessels reperfused ischemic heart tissue. Thus, agents that modulate the redox environment of the heart are potentially useful for treating coronary heart disease. For this reason, our laboratory has been characterizing thioredoxin (Trx), an endogenous enzyme that can reduce oxidative stress and regenerate proteins that have been inactivated by oxidation. In conjunction with this research, we developed two transgenic mouse lines that have altered Trx activity: one (Trx-Tg) overexpresses the protein, whereas the other (dnTrx-Tg) expresses an inactive Trx and thus acts as a conditional Trx knockout. As we characterized these unique mice, we discovered that aged TrxTg mice are protected against myocardial infarction in response to ischemia- reperfusion (I/R), whereas those deficient in Trx, like wild type, undergo extensive myocardial damage. Thus, we hypothesize that increased levels of Trx activity can afford protection against endothelial dysfunction. This hypothesis leads to the Specific Aims of this proposal: Aim 1 will establish the role of Trx in endothelial dysfunction arising from I/R injury; Aim 2 will explore potential mechanisms of these effects; and Aim 3 will determine whether Trx increases the expression of mitochondrial superoxide dismutase as a contributor to protection against endothelial dysfunction. The outcomes of this project will contribute to our understanding of endothelial cell dysfunction in cardiovascular diseases such as atherosclerosis, and propel the development of Trx as a real novel therapeutic approach to treat cardiovascular disease as exogenously added Trx is avidly taken up by endothelial cells.
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/gt.2011.133
发表时间: 2012-05
期刊: Gene therapy
影响因子: 5.1
作者: []
通讯作者:
DOI: 10.18632/aging.104071
发表时间: 2020-10-13
期刊: Aging
影响因子: --
作者: [Subramani J, Kundumani-Sridharan V, Das KC]
通讯作者: Das KC
DOI: 10.1016/j.exger.2013.06.002
发表时间: 2013-09
期刊: EXPERIMENTAL GERONTOLOGY
影响因子: 3.9
作者: [Das, Kumuda C., Muniyappa, Harish]
通讯作者: Muniyappa, Harish
DOI: 10.1126/scitranslmed.aaf6094
发表时间: 2017-02-08
期刊: Science translational medicine
影响因子: 17.1
作者: [Hilgers RH, Kundumani-Sridharan V, Subramani J, Chen LC, Cuello LG, Rusch NJ, Das KC]
通讯作者: Das KC
12
    Vascular dysfunction in coronary microcirculation
    Vascular dysfunction in coronary microcirculation
    Endothelial Mechanism In RIPC
    Endothelial Mechanism In RIPC
    国内基金
    海外基金
    补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
    靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
    • 批准号:
      JCZRQN202500010
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
    • 依托单位:
    对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
    • 批准号:
      2025JJ70209
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      雷芬芳
    • 依托单位:
    AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
    • 批准号:
      --
    • 项目类别:
      面上项目
    • 资助金额:
      --
    • 批准年份:
      2024
    • 负责人:
      万荣
    • 依托单位: